Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer: State of the art
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer: State of the art作者机构：Division of Gyneco-logic Oncology Department of Obstetrics and Gynecology Irvine Medical Center University of California Irvine CA 92868United States Department of General and Emergency Surgery Ospedali Riuniti 24100 Bergamo Italy
出 版 物：《World Journal of Obstetrics and Gynecology》 (世界妇产科杂志)
年 卷 期：2013年第2卷第4期
页 面：94-100页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Epithelial ovarian cancer Cytoreductive surgery Hyperthermic intraperitoneal chemotherapy Intraperitoneal chemotherapy Survival Toxicity
摘 要：Advanced stage epithelial ovarian cancer(EOC) is diffi cult to treat with low overall cure rates. A new strategy combining maximal cytoreductive surgery(CRS) with intraoperative hyperthermic intraperitoneal chemotherapy(HIPEC) has been proposed to treat advanced stage EOC in the primary setting. Numerous small, heterogeneous studies have been conducted exploring outcomes in patients with predominantly advanced, recurrent or refractory disease treated with CRS + HIPEC. Although morbidity rates approaching 35% have been reported, oncologic outcomes are promising. Incorporation of HIPEC for the treatment of primary EOC has continued to gain interest. Several prospective phase 2 clinical trials were recently completed evaluating the impact of CRS + HIPEC in the primary setting. This article will briefl y discuss the benefi ts of optimal surgical cytoreduction and the theoretical basis of intraperitoneal chemotherapy in patients with advanced stage EOC, and will then review existing literature describing oncologic outcomes in EOC patients treated with HIPEC in the primary setting.
维普期刊数据库